Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Daniel Rudolph

Pulmonary Disease Trumbull, CT Medical Doctor

NPI 1356335707 CMS profile 15570

15 Corporate Dr, Trumbull, CT 06611

Open in the dashboard

General payments

$2,255

109 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Daniel Rudolph of Trumbull, CT is reported in the CMS Open Payments database as having received $2,255 across 109 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 54th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $186 4
2023 General $16 1
2022 General $20 1
2020 General $388 14
2019 General $1,645 89

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Rudolph
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Daniel Rudolph were reported at $0. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Daniel Rudolph Pulmonary Disease median Middle half National median
2019 $1,645 $377 $109–$1,340 $163
2020 $388 $230 $56–$907 $114
2021 $0 $269 $68–$1,072 $132
2022 $20 $390 $100–$1,457 $149
2023 $16 $419 $114–$1,659 $160
2024 $186 $476 $123–$1,818 $164
2025 $0 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. GlaxoSmithKline, LLC. $630 33 payments
  2. AstraZeneca Pharmaceuticals LP $339 14 payments
  3. Baxter Healthcare $202 5 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $178 7 payments
  5. Insmed, Inc. $172 4 payments
  6. Sunovion Pharmaceuticals Inc. $119 12 payments
  7. Novartis Pharmaceuticals Corporation $118 5 payments
  8. Genentech USA, Inc. $108 6 payments
  9. Shire North American Group Inc $87 5 payments
  10. Mallinckrodt Enterprises LLC $51 3 payments
  11. Other $252 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $2,255 109 payments
Products named General payments · program years 2019–2024
  1. TRELEGY ELLIPTA $411 17 payments
  2. FASENRA $310 12 payments
  3. Hillrom - Vest System Model 105 Home Care $202 5 payments
  4. Arikayce $172 4 payments
  5. OFEV $157 6 payments
  6. NUCALA $138 12 payments
  7. LONHALA MAGNAIR $119 12 payments
  8. XOLAIR Respiratory $118 5 payments
  9. Xolair Immunology $108 6 payments
  10. ANORO $97 4 payments
  11. Other $577 34 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

2,590

Median for Internal Medicine: 777

Drug cost

$861,495

Median for Internal Medicine: $73,373

Branded share of claims

62.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 460 $468,131
Breo Ellipta Fluticasone/Vilanterol Brand 181 $145,650
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 62 $66,513
Symbicort Budesonide/Formoterol Fumarate Brand 76 $27,062
Eliquis Apixaban Brand 33 $21,807
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 24 $20,379
Arnuity Ellipta Fluticasone Furoate Brand 52 $17,828
Spiriva Respimat Tiotropium Bromide Brand 18 $16,005
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 66 $15,351
Spiriva Handihaler Tiotropium Bromide Brand 12 $14,966

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$124,503

Of which drugs: $1,947

Medicare patients

557

Average age 78

Services billed

1,568

337 women, 220 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 61%
Arthritis 57%
Ischemic heart disease 46%
Diabetes 32%
Heart failure 32%
Atrial fibrillation 29%
Cancer 27%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 16 16 $1,309

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

109 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record